Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SER 109

Drug Profile

SER 109

Alternative Names: SER-109

Latest Information Update: 08 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seres Health
  • Developer Seres Therapeutics
  • Class Anti-infectives; Bacteria
  • Mechanism of Action Bacteria replacements; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium difficile infections
  • New Molecular Entity No

Highest Development Phases

  • Phase III Clostridium difficile infections

Most Recent Events

  • 03 May 2019 Seres Therapeutics plans to file BLA with the US FDA for Clostridium difficile infections
  • 05 Oct 2018 Pooled sub-group efficacy data from a phase Ib and a phase II trial in Clostridium difficile infections presented at the IDWeek 2018 (IDW-2018)
  • 09 Nov 2017 Health Canada clears clinical trial application for phase III ECOSPOR III study
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top